|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1995; 26:1022-1029 © 1995 by the American College of Cardiology Foundation |
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-7934, USA.
OBJECTIVES. We used electrocardiographic (ECG) and echocardiographic measurements from 3,351 adults from the Framingham Heart Study to evaluate the performance of 10 ECG criteria in detecting left ventricular hypertrophy before and after adjustment for gender, age and obesity. BACKGROUND. Significant improvement in the sensitivity and specificity of ECG voltage-based criteria for detection of echocardiographic left ventricular hypertrophy using gender-specific criteria adjusted for age and obesity has been demonstrated. METHODS. Gender-specific correlation and regression analyses were used to identify the five most sensitive ECG criteria and to adjust them for age and obesity. Standard and truncated receiver operating characteristic curves were used to compare the selected criteria. RESULTS. Linear regression of left ventricular mass on ECG voltages, body mass index and age yielded considerably stronger relations for women than for men because of the greater correlation between ventricular mass and body mass index in women. Obesity and age adjustment of the five voltage criteria produced considerable improvement in their performance. The voltage sum of the R wave in lead aVL and the S wave in lead V3, alone and in combination with QRS duration, had a sensitivity at 95% specificity of 32% and 39%, respectively, in men and 46% and 51%, respectively, in women after adjustment. Tables of critical voltages for the adjusted criteria and representative performance values are presented. CONCLUSIONS. Incorporation of obesity and age in ECG algorithms consistently improves their performance in the detection of hypertrophy. The development of such criteria will enhance the utility of this inexpensive screening test. Such ECG approaches should be used in clinical trials to assess the efficacy of antihypertensive treatment to effect regression of left ventricular hypertrophy. A search for further improvements in the efficacy of ECG criteria for this purpose is warranted. Independent validation of this approach is needed.
This article has been cited by other articles:
|
|
 |
|
  T. A. Aksnes, S. E. Kjeldsen, M. Rostrup, P. Omvik, T. A. Hua, and S. Julius Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population Hypertension, September 1, 2007; 50(3): 467 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Giunti, G. Bruno, E. Lillaz, G. Gruden, V. Lolli, N. Chaturvedi, J. H. Fuller, M. Veglio, P. Cavallo-Perin, and The EURODIAB IDDM Complications Study Group Incidence and Risk Factors of Prolonged QTc Interval in Type 1 Diabetes: The EURODIAB Prospective Complications Study Diabetes Care, August 1, 2007; 30(8): 2057 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Giunti, G. Bruno, M. Veglio, G. Gruden, D. J. Webb, S. Livingstone, N. Chaturvedi, J. H. Fuller, P. C. Perin, and the EURODIAB IDDM Complications Study Group Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes: Prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study Diabetes Care, September 1, 2005; 28(9): 2255 - 2257. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, et al. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events JAMA, November 17, 2004; 292(19): 2343 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Alfakih, K. Walters, T. Jones, J. Ridgway, A. S. Hall, and M. Sivananthan New Gender-Specific Partition Values for ECG Criteria of Left Ventricular Hypertrophy: Recalibration Against Cardiac MRI Hypertension, August 1, 2004; 44(2): 175 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. J. Mancini, B. Dahlof, and J. Diez Surrogate Markers for Cardiovascular Disease: Structural Markers Circulation, June 29, 2004; 109(25_suppl_1): IV-22 - IV-30. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, et al. Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study Circulation, August 12, 2003; 108(6): 684 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kjeldsen, B. Dahlof, R. B. Devereux, S. Julius, P. Aurup, J. Edelman, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, et al. Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy: A Losartan Intervention For Endpoint Reduction (LIFE) Substudy JAMA, September 25, 2002; 288(12): 1491 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, R. B. Devereux, M. S. Nieminen, S. Jern, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, S. Julius, B. Dahlof, et al. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study J. Am. Coll. Cardiol., August 1, 2001; 38(2): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, and B. Dahlof Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients : The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study Hypertension, November 1, 2000; 36(5): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jaggy, F. Perret, P. Bovet, G. van Melle, N. Zerkiebel, G. Madeleine, L. Kappenberger, and F. Paccaud Performance of Classic Electrocardiographic Criteria for Left Ventricular Hypertrophy in an African Population Hypertension, July 1, 2000; 36(1): 54 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, S. Jern, R. B. Devereux, S. E. Kjeldsen, B. Dahlof, and f. t. L. S. Group Effect of Obesity on Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients : The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Hypertension, January 1, 2000; 35(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dahlof, R. B. Devereux, S. Julius, S. E. Kjeldsen, G. Beevers, U. de Faire, F. Fyhrquist, T. Hedner, H. Ibsen, K. Kristianson, et al. Characteristics of 9194 Patients With Left Ventricular Hypertrophy : The LIFE Study Hypertension, December 1, 1998; 32(6): 989 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Hsue, C. L. Salinas, A. F. Bolger, N. L. Benowitz, and D. D. Waters Acute Aortic Dissection Related to Crack Cocaine Circulation, April 2, 2002; 105(13): 1592 - 1595. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
